Antisense oligomers and methods for inducing immune tolerance and immunosuppression

• US 8,415,313 B2
• Filed: 05/11/2006
• Issued: 04/09/2013
• Est. Priority Date: 01/23/2004
• Status: Active Grant

• Current Assignee: Sarepta Therapeutics, Inc.
• Original Assignee: Avi Biopharma, Inc.
• Inventors: Mourich, Dan V., Iversen, Patrick L., Weller, Dwight D.
• Primary Examiner(s): GIBBS, TERRA C
• Application Number:
  US11/433,033
• Publication Number:
  US 20060276425A1
• Time in Patent Office: 2,525 Days
• Field of Search: 514/44, 435/6, 435/91.1, 435/325, 435/375, 536/23.1, 536/24.3, 536/24.33, 536/24.5
• US Class Current: 514/44.A
• CPC Class Codes: A61K 31/675 having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• CPC Class Codes: C12N 15/1138 against receptors or cell surface proteins
• CPC Class Codes: C12N 2310/11 Antisense
• CPC Class Codes: C12N 2310/3233 Morpholino-type ring
• CPC Class Codes: C12N 2310/3513 Protein; Peptide

Abstract

A method and composition for inducing human dendritic cells to a condition of reduced capacity for antigen-specific activation of T cells, and, in mature dendritic cells, increased production of extracellular IL-10 is disclosed. A population of dendritic cells is exposed to a substantially uncharged antisense compound, including partially positively charged, containing 12-40 subunits and a base sequence effective to hybridize to a target region within the sequence identified by SEQ ID NO:9, to form a duplex structure between the compound and transcript having a Tm of at least 45° C. Formation of the duplex blocks expression of full-length CD86 in the cells, which in turn leads to reduced capacity for antigen-specific activation of T cells, and, in mature dendritic cells, increased production of extracellular IL-10.

Claims

1. A method of inducing increased production of extracellular IL-10 in mature dendritic cells, comprising

(a) exposing a population of human dendritic cells that includes mature dendritic cells to an antisense compound composed of phosphorus-containing intersubunit linkages joining a morpholino nitrogen of one subunit to a 5′

exocyclic carbon of an adjacent subunit and containing 12-40 subunits, including a base sequence of at least 12 contiguous bases that are complementary to a target region within the sequence identified by SEQ ID NO;

9, wherein said compound is covalently linked, at one compound end, to an arginine-rich peptide effective to enhance uptake of said compound into the mature dendritic cells, and

(b) by said exposing in step (a), blocking expression of full-length CD86 in said cells,

(c) by said blocking, thereby producing inhibition of the expression of full-length CD86 on the surface of mature dendritic cells, and enhanced expression of extracellular IL-10 by mature dendritic cells.

2. The method of claim 1, wherein the morpholino subunits in the compound to which the dendritic cells are exposed are joined by phosphorodiamidate linkages, in accordance with the structure:

3. The method of claim 1, in which at least 2 and no more than half of the total number of intersubunit linkages are cationic linkages, wherein said morpholino subunits are joined by phosphorodiamidate linkages, in accordance with the structure:

4. The method of claim 2, wherein X═

NR₂, where each R is independently hydrogen or methyl in the compound to which the T cells are exposed.

5. The method of claim 1, wherein said arginine-rich peptide has a sequence selected from the group consisting of SEQ ID NOS:

1 and 2.

6. The method of claim 1, wherein said dendritic cells which are exposed to said compound include a mixture of immature and mature dendritic cells, said compound is covalently linked to an arginine-rich rTAT peptide having the sequence identified by SEQ ID NO:

1, and the rTAT peptide is effective to achieve a greater level of intracellular uptake of the antisense compound into the mature dendritic cells than is achieved (i) in the immature dendritic cells, or (ii) by exposing the mature dendritic cells to the antisense compound in the absence of the rTAT polypeptide.

7. The method of claim 1, wherein the antisense compound includes a base sequence selected from the group consisting of:

SEQ ID NOS;

21-23 and 32.

8. The method of claim 1, for use in inhibiting transplantation rejection in a human subject receiving an allograft tissue or organ, wherein said exposing includes administering the antisense compound to the subject, in an amount effective to inhibit the rate and extent of rejection of the transplant.

9. The method of claim 8, wherein said administering is carried out both prior to and following the allograft tissue or organ transplantation in the subject.

10. The method of claim 8, wherein said administering is carried out for a selected period of 1-3 weeks.

11. The method of claim 10, which further includes further administering the antisense compound to the subject, as needed, to control the extent of transplantation rejection in the subject.

12. The method of claim 1, for use in treating an autoimmune condition in a human subject, wherein said exposing includes administering the antisense compound to the subject, in an amount effective to reduce the severity of the autoimmune condition.

13. The method of claim 12, wherein said administering is carried out over an extended period of time, as needed, to control the severity of the autoimmune condition in the subject.

14. A method of inducing mature human dendritic cells to a condition of increased production of extracellular IL-10, comprising

(a) exposing a population of human dendritic cells that comprises mature dendritic cells to an antisense compound composed of phosphorus-containing intersubunit linkages joining a morpholino nitrogen of one subunit to a 5′

exocyclic carbon of an adjacent subunit and containing 12-40 subunits, including a base sequence of at least 12 contiguous bases that are complementary to a target region within the sequence identified by SEQ ID NO;

9, wherein said compound is covalently linked to an arginine-rich rTAT peptide having the sequence identified by SEQ ID NO;

1, and

(b) by said exposing in step (a), blocking expression of full-length CD86 in said cells,

(c) thereby enhancing expression of extracellular IL-10 by the mature dendritic cells.